A Phase 1, Multicenter, Open-label Study to Investigate the Safety and Biodistribution of a Single Intrathecal Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (The ASCEND Study)
Latest Information Update: 05 Jun 2025
At a glance
- Drugs INS 1201 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms The ASCEND Study
- Sponsors Insmed
Most Recent Events
- 08 May 2025 According to an Insmed media release, company initiated trial for patients with Duchenne muscular dystrophy (DMD), in the first quarter of 2025, and expects to dose the first patient in the second quarter of 2025.
- 11 Apr 2025 Planned initiation date (estimated date of first participant enrollment) changed from 7 Feb 2025 to 31 May 2025.
- 11 Apr 2025 Status changed from not yet recruiting to recruiting.